The European Commission has approved the use of abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with early-stage breast cancer HR + and HER2-, node-positive and at high risk of relapse. The monarchE phase 3 randomized trial showed a statistically significant improvement in invasive disease-free survival in patients receiving abemaciclib plus hormone therapy compared with patients re...
A new therapeutic option for patients with early breast cancer
Fot. MedExpress TV
Although the prognosis for early breast cancer HR +, HER2- is good, 20-30% of patients may develop an incurable metastatic disease. A new treatment option is available for these patients.
Topicswczesny rak piersi